Investing.com -- CRISPR Therapeutics AG (NASDAQ:CRSP)股票周五飙升超过16%，在公司一名董事大量购入股票后创下52周新高。
董事Simeon George在提交给美国证券交易委员会的文件中披露，他购买了价值约5150万美元的公司股票。根据监管文件，George于7月16日以每股52.03美元的价格购买了总计989,812股普通股。
这些购买是通过各种投资工具进行的。文件显示，George通过SR One Capital Fund II Aggregator购买了6,510股，通过SR One Capital Opportunities Fund I购买了22,319股，并通过AMZL, LP购买了960,983股。所有这些实体都与SR One Capital Management有关联，George在该公司担任唯一管理成员。
这一重大内部人士购买行为发生在CRISPR Therapeutics继续开发基因编辑疗法之际。在披露该消息后，该股票达到新高，反映出投资者在董事大量投资后信心增强。
本文由人工智能协助翻译。更多信息，请参见我们的使用条款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.